TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 176 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,887,800 | -41.8% | 7,370,000 | 0.0% | 2.54% | -51.5% |
| Q2 2023 | $113,203,200 | -18.1% | 7,370,000 | +19.9% | 5.24% | -7.7% |
| Q1 2023 | $138,252,057 | +43.5% | 6,147,268 | +34.2% | 5.68% | +40.3% |
| Q4 2022 | $96,359,460 | -2.2% | 4,582,000 | +14.6% | 4.05% | -10.4% |
| Q3 2022 | $98,560,000 | +13.6% | 4,000,000 | +11.7% | 4.51% | -20.8% |
| Q2 2022 | $86,760,000 | +7.4% | 3,580,700 | +14.2% | 5.70% | +10.1% |
| Q1 2022 | $80,776,000 | +6.2% | 3,134,503 | +27.9% | 5.18% | -3.5% |
| Q4 2021 | $76,048,000 | – | 2,450,000 | – | 5.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |